tracxn research — genomics landscape, november 2016

Genomics Report – November 2016

TracxnWorld’s Largest Startup Research Platform

2


Contents

Topic Page No.

Scope of Report 04

Entrepreneur Activity 06

Investment Trend 08

Who is Investing 19

Exit Outlook - IPO, Acquisitions 23

Sub Sector Analysis 27

Interesting Companies 46

Company List 54

Team 143


Sector Overview

Scope of report

The report includes companies which are providing products and services for high-throughput sequencing; developingsequencing technologies; developing tools (or softwares) and providing services for sequencing data analysis; providingdiagnostic products and services that use high-throughput sequencing to assess the risk of development of disease inasymptomatic individuals, detect presence of a disease/condition, or to determine best treatment regimens for diagnosedpatients.

We have excluded clinical laboratories that provides sequencing services for diagnostics without their own proprietarytechnology.

The scope of this report includes equity as well as debt funding received by the companies.


Scope of Report

Entrepreneur Activity

Investment Trend

Who is Investing

Exit Outlook - IPO, Acquisitions

Sub Sector Analysis

Interesting Companies

Company List

Team

5


39

54

64

70

79

49

10

0

18

36

54

72

90

2010 2011 2012 2013 2014 2015 2016

Nu

mb

er o

f C

om

pan

ies

6

YoY – Number of companies founded

Foundation Medicine Personalis Guardant Health Human Longevity Inivata iCarbonX Grail Bio

Med fusion Fulgent Diagnostics Invitae Color Genomics Arivale Helix ReadCoor


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

7


YoY – Number of Rounds and Total Funding

Note: The funding includes debt rounds also.

$146M

$327M

$646M

$373M

$560M $536M

$1.5B

$1.6B

$1.7B

25

45

53

44

76 76

89

113

91

0

24

48

72

96

120

0

360

720

1080

1440

1800

2008 2009 2010 2011 2012 2013 2014 2015 2016

Nu

mb

er of R

ou

nd

sFu

nd

ing

Am

ou

nt

(in

Mill

ion

s)

Funding Amount Number of Rounds


YoY – Number of Rounds by Stage

7

22 24 23

39

19

25

34 33

46

47

56

12

16 16

17

19

13

0

24

48

72

96

120

2011 2012 2013 2014 2015 2016

Nu

mb

er o

f R

ou

nd

s

Seed Early Late


YoY – Funding by Stage

$6M $16M $17M $24M $35M $17M$171M

$255M$193M

$875M

$603M

$1.3B

$195M

$279M $322M

$438M

$727M

$414M

0

400

800

1200

1600

2000

2011 2012 2013 2014 2015 2016

Tota

l Fu

nd

ing

Am

ou

nt

(in

Mill

ion

s)

Seed Early Late


Average Ticket Size – Early Stage

$0.9M $0.9M $0.8M$1.3M $1.1M $0.9M

$6.7M$5.5M $4.0M

$7.8M

$13.0M

$23.5M

$8.4M $8.6M$8.0M

$45.7M

$17.6M

$29.1M

0.0

10.0

20.0

30.0

40.0

50.0

2011 2012 2013 2014 2015 2016

Fun

din

g A

mo

un

t (i

n M

illio

ns)

Seed Series A Series B


Top investments in last one year (1/5)

CompanyFunding Amount

Round Name

Date Investors

humanlongevity.comHuman Longevity(San Diego, 2013)

$220M Series B Apr-2016 GE Ventures, Illumina, Celgene

icarbonx.comiCarbonX

(Shenzhen, 2015)$155M Series A Apr-2016 Zhongyuan Union Stem Cell Bioengineering, Tencent

23andme.com

23andMe(Mountain View,

2006)$115M Series E Oct-2015

Fidelity Investments, WuXi Healthcare Ventures, Casdin Capital, Illumina, NEA, MPM Capital, GV, Xfund

grailbio.comGrail Bio

(San Diego, 2016)$100M Series A Jan-2016 Illumina, ARCH Venture Partners, Sutter Hill Ventures, Bezos Expeditions

guardanthealth.comGuardant Health

(Redwood City, 2012)$100M Series D Jan-2016

Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar Ventures, Formation 8, Heritage Group

lasergen.comLasergen

(Houston, 2002)$80M PE Mar-2016 Agilent

codiakbio.comCodiak BioSciences

(Woburn, 2015)$61M Series B Jan-2016

Flagship Ventures, ARCH Venture Partners, Alexandria Real Estate Equities, Fidelity Investments




Round Name

Date Investors

10xgenomics.com10X Genomics

(Pleasanton, 2012)$55M Series C Mar-2016 Paladin Capital Group, SoftBank, Fidelity Investments, Foresite Capital, Venrock

nanthealth.comNantHealth

(Culver City, 2007)$53M Series C Jan-2016

getcolor.comColor Genomics

(Burlingame, 2013)$45M Series B Sep-2016 General Catalyst Partners, 8VC, Khosla Ventures, 8VC

inivata.comInivata

(Cambridge, 2014)$45M Series A Jan-2016

Imperial Innovations, Cambridge Capital Group, JJDC, Woodford Investment Management

sbgenomics.com

Seven Bridges Genomics

(Cambridge, 2009)$45M Series A Feb-2016


(Shenzhen, 2015)$45M Series A Jul-2016 China Bridge Capital

accuragen.comAccuraGen

(Menlo Park, 2013)$40M Series B Jun-2016 Decheng Capital, Temasek, DT Capital Partners, StartX, Nan Fung Group

pathway.comPathway Genomics(San Diego, 2008)

$40M Series E Jan-2016 IBM Watson




Round Name

Date Investors

codiakbio.comCodiak BioSciences

(Woburn, 2015)$31M Series A Nov-2015

ARCH Venture Partners, Fidelity Investments, Alexandria Real Estate Equities, Flagship Ventures

veritasgenetics.comVeritas Genetics(Danvers, 2014)

$30M Series B Oct-2016 Lilly Asia Ventures, Trustbridge Partners, Simcere Pharma

fulgentdiagnostics.comFulgent Diagnostics(Temple City, 2011)

$27M Series A May-2016

centrilliontech.com

CentrillionTechnologies

(Palo Alto, 2009)$27M Series C May-2016

syapse.comSyapse

(Palo Alto, 2008)$25M Series C Jan-2016 Ascension Ventures, Social Capital, Safeguard Scientifics

omicia.comOmicia

(Oakland, 2009)$23M Series B Jun-2016 UPMC, Roche, LDV Partners, Ping An Ventures, ARTIS Ventures

readcoor.comReadCoor

(Cambridge, 2016)$23M Series A Sep-2016 Decheng Capital, Lilly Asia Ventures, Vivo Capital

biodesix.comBiodesix

(Broomfield, 2005)$22M Series F Feb-2016




Round Name

Date Investors

personalgenome.comPersonal Genome(Baltimore, 2010)

$21M Series A Oct-2015 NEA, Windham Venture Partners

cambridge-epigenetix.comCambridge Epigenetix

(Cambridge, 2012)$21M Series B Mar-2016 GV, Sequoia Capital, Syncona Partners, New Science Ventures, University of Cambridge

genomind.com

Genomind(King Of Prussia,

2009)$21M Series A Jul-2016 Claritas Capital

singleragenomics.comSinglera Genomics

(La Jolla, 2014)$20M Series A Aug-2016 Lilly Asia Ventures, Green Pine Capital Partners, CDBI Partners

purigenbio.comPurigen Biosystems(Pleasanton, 2012)

$18M Series A May-2016 5AM Ventures, Roche, StartX

pillar-biosciences.comPillar Biosciences

(Natick, 2013)$18M Series A May-2016

enterome.frEnterome

(Paris, 2012)$17M Series C Apr-2016 Seventure Partners, Lundbeckfond Ventures, Nestle Health Science

exosomedx.comExosome Diagnostics(New York City, 2008)

$15M Series B Jan-2016




Round Name

Date Investors


(Shenzhen, 2015)$15M Series A Jan-2016 Zhongyuan Union Stem Cell Bioengineering

assurexhealth.comAssurex Health(Mason, 2006)

$15M Series D Dec-2015Sequoia Capital, Mayo Clinic, Claremont Creek Ventures, Cincinnati Childrens Hospital Medical Center, Cross Creek Advisors

clinicalgenomics.comClinical Genomics

(Sydney, 2006)$15M Series A Mar-2016 One Ventures

sophiagenetics.comSophia Genetics(Lausanne, 2011)

$15M Series C Dec-2015

caredxinc.comCareDx

(Brisbane, 2000)$14M PE Apr-2016

actgenomics.comACT Genomics(Taipei, 2014)

$13M Series B May-2016 Hotung Group, China Development Financial Holding, pidc.com.tw, UMC Capital

strataoncology.comStrata Oncology

(Ann Arbor, 2015)$12M Series A Jun-2016 Arboretum Ventures, Baird Capital, eLab Ventures

bluebee.comBluebee

(Delft, 2011)$11M Series A Mar-2016 Capricorn Venture Partners, Korys, Buysse & Partners


Funnel view of Sector

Percent of Previous

67%

58%

45%

88

58

112

249

428

642

0 140 280 420 560 700

M&A & IPO

Late

Series B

Series A

Funded

Founded

Number of Companies


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

18


Most Active Investors in Sector

8 8 8

7 7

6 6

5 5 5

0

2

4

5

7

9

Mohr DavidowVentures

Orbimed SequoiaCapital

ARCH VenturePartners

Illumina KPCB Sutter HillVentures

CasdinCapital

IndieBio Roche

Tota

l Nu

mb

er o

f R

ou

nd

s

PacificBiosciences

Guardant Health Guardant Health IlluminaOxford Nanopore

TechnologiesPacific

BiosciencesPacific

BiosciencesAdaptive

BiotechnologiesRanomics

Foundation Medicine

23andMe Invitae Natera Grail BioAdaptive

BiotechnologiesCareDx Illumina 23andMe Girihlet

StratosGenomics


Where are Top Investors investing


Top Investor by Stage of Entry


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

22


Top IPOs in last three years

IPO Date Company OverviewFunding Amount

Ticker

Jun-2016 nanthealth.comNantHealth

(Culver City, 2007)

Combining medical data and patients' genetic information to find individualized treatment for cancer and other diseasesBlackberry, Blackstone, Verizon, Allscripts, Celgene, Kuwait Investment Authority

$765M NH

Nov-2015 oncovista.comOncoVista

(San Antonio, 2004)

Develops therapeutics and diagnostics for cancer.Chicago Venture Partners $65M OVIT

Jun-2015 natera.comNatera

(Redwood City, 2004)

Diagnostics company specializing in prenatal and pre-implantation diagnostics.Lightspeed Venture Partners, Sequoia Capital, Orbimed, Founders Fund, Sofinnova Ventures, Harmony Partners, Claremont Creek Ventures, RA Capital Management, Alafi Capital, Jennison Associates, Franklin Templeton, HRC Fertility, Capital Group, Claremont Creek Ventures, HealthCor Partners

$152.1M NTRA

Feb-2015 invitae.comInvitae

(San Francisco, 2012)

A genetic information company.Orbimed, Casdin Capital, Thomas, The Broe Group, Decheng Capital, Deerfield, Genesys Capital, Genomic Health, Wellington Management, Rock Springs Capital, Redmile Group, Perceptive Advisors

$189.56M NVTA

Jul-2014 caredxinc.comCareDx

(Brisbane, 2000)

Predicting risk of transplant rejection for heart transplant patients.KPCB, Intel Capital, Silicon Valley Bank, Integral Capital Partners, TPG Growth, Duff Ackerman & Goodrich, Burrill and Company, New Leaf Ventures, Sprout Group, TPG, Double Bottom Line Investors, Oxford Finance, Leader Ventures, Bristol-Myers Squibb, gehealthcarefinance.com, DBL Partners

$114.82M CDNA

Nov-2013 veracyte.comVeracyte

(San Francisco, 2008)

Genomic solutions for cancer diagnosticsKPCB, TPG, Versant Ventures, Domain Associates, GE Ventures $95.65M VCYT


Major Acquisitions in last one year (1/2)


Major Acquisitions in last one year (2/2)


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

26


October 2016Tracxn BlueBox : Biotech 4800+ companies in the sector, 2369 funded in last 5 years, over $18.6B invested since ‘15


October 2016Tracxn BlueBox : Diagnostics (Tech)1720+ companies in the sector, 810 funded in last 5 years, $4.8B+ invested in 2015/16


Top Business Models by Funding

$2.0B

$1.8B

$1.5B

$1.3B

$1.0B

$0.7B

0.0

0.5

1.0

1.5

2.0

2.5

Clinical Genomics Bioinformatics Sequencing Technology Genetic Testing Liquid Biopsy Research Genomics

Tota

l Fu

nd

ing

Am

ou

nt

(in

Bill

ion

s)

# Cos. 196 193 31 82 53 87

Avg. Age Jan-09 Apr-09 Apr-07 Jan-09 Jul-09 Nov-06

Adaptive Biotechnologies NantHealth Oxford Nanopore Technologies 23andMe Guardant Health 10X Genomics

CareDx Human Longevity Pacific Biosciences Invitae Biodesix RainDance Tech


Clinical Genomics – Business Model Description


Clinical Genomics – Entrepreneur Activity and Investment Trend


Clinical Genomics – Most Funded Companies


Bioinformatics – Business Model Description


Bioinformatics – Entrepreneur Activity and Investment Trend


Bioinformatics – Most Funded Companies


Sequencing Technology – Business Model Description


Sequencing Technology – Entrepreneur Activity and Investment Trend


Sequencing Technology – Most Funded Companies


Genetic Testing – Business Model Description


Genetic Testing – Entrepreneur Activity and Investment Trend


Genetic Testing – Most Funded Companies


Liquid Biopsy – Business Model Description


Liquid Biopsy – Entrepreneur Activity and Investment Trend


Liquid Biopsy – Most Funded Companies


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

45


Interesting Unfunded Companies

Company Overview Business Model

tempus.comTempus

(2015, Chicago)

Oncology platform for sequencing, analytics and informaticsBioinformatics > Clinical Informatics

avatardss.comAvatar DSS

(2015, Tampa)

Precision treatment support for cancer patients Bioinformatics > Clinical Informatics > Pharmacogenomics

Vital Genomics (2015, Boca Raton)

Provide physicians with pharmacogenomics technology, training, educational support, and patient communications

Clinical Genomics > Pharmacogenomics

Saga Diagnostics(2016, Lund)

Tests for detection and analysis of circulating tumor DNA Liquid Biopsy

Lifenome(2015, NYC)

Genomics-driven personal wellness Genetic Testing > Nutrigenomics

Curated list of companies by the sector analyst are defined as Interesting


Interesting Seed Companies


Interesting Series A Companies


Interesting Series B Companies


Interesting Late Stage Companies


Top Funded Deadpooled Companies


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

53


Genomics – Company List

Clinical Genomics Bioinformatics Sequencing Technology

Genetic Testing Liquid BiopsyResearch Genomics

428 FUNDED COMPANIES AND 214 UNFUNDED COMPANIES

COVERS THE FOLLOWING SECTORS


Clinical Genomics (1/26)Company Overview Business Model Total Funding

MDxHealth(2003, Irvine)

Epigenetic tests for personalized cancer assessment and treatment.Seventure Partners, Idinvest Partners, IWT, EuroTransBio, IPSA Epigenetics $94.14M

Epigenomics(1998, Berlin)

Molecular Diagnostics for CancerWellcome Trust, 3i Group, MPM Capital, Abingworth, DVCG, BioChain, Creathor Venture, European Commission

Epigenetics $52.05M

OncoMethylome(2003, Antwerp)

Diagnostics for early detection of cancerEpigenetics $16M

Nucleix(2008, Rehovot)

Develops non-invasive molecular cancer diagnostic testsOrbimed, Aurum Ventures Epigenetics $11.5M

Oxford Biodynamics(2007, Oxford)

Biomarker discovery based on epigenetics for personalized diagnostics.Epigenetics $11M

MetaStat(2007, Montclair)

Develops and commercializes diagnostic tests for the prediction of cancer metastasis.H.C. Wainwright

Epigenetics $1.5M

Oncgnostics(2012, Jena)

Develops epigenetic biomarkers diagnostic testsHigh-Tech Grunderfonds, Bm-t Beteiligungsmanagement Thuringen, Sparkasse Jena Saale Holzland, STIFT

Epigenetics

Episona(2013, Los Angeles)

Test kit using epigenetics to test male infertility.Epigenetics

Go to BM List >> Bioinformatics



RiboMed Biotechnologies(1999, Carlsbad)

Personalized diagnostics, prognostics and theranostics based on epigenetics. Epigenetics

PrognosDx Health(2008, Palo Alto)

Epigenetic testing technology to identify cancerEpigenetics

Behavioral Diagnostics(2009, Iowa City)

Epigenetics based substance use diagnosticsNational Institutes of Health Epigenetics

Adaptive Biotechnologies(2009, Seattle)

Engages in immune-based discoveries and diagnostics by combining high-throughput sequencing & bioinformatics to profile immune cell receptors genes.Illumina, Tiger Global Management, Matrix Partners, Casdin Capital, Celgene, Alexandria Real Estate Equities, BD Biosciences, Foresite Capital, Laboratory Corporation of America, Rock Springs Capital, Viking Global Investors, Senator Investment, National Heart Lung and Blood Institute

Immunosequencing $404.35M

Sequenta(2008, San Francisco)

Immunesequencing for blood cancersIndex Ventures, Mohr Davidow Ventures, Celgene, Foresite Capital Immunosequencing $43.46M

Repertoire(2014, Ibaraki)

TCR/BCR repertoire analysis servicesThe University of Tokyo Edge Capital, Beyond Next Ventures Immunosequencing $6.47M

MIODx(2014, San Jose)

Diagnostics based on genomics and immunesequencing.Immunosequencing $1.5M




ImmunID(2005, Grenoble)

Molecular diagnostics using immune profilingImmunosequencing

Enterome(2012, Paris)

Therapeutic solutions for diseases associated with abnormalities of the gut microbiome (such as Inflammatory Bowel Diseases).Omnes Capital, Seventure Partners, Lundbeckfond Ventures, INRA Transfert, Lundbeckfonden, Nestle Health Science

Microbiomics $39.16M

uBiome(2012, San Francisco)

Citizen science startup to sequence the human microbiome.Andreessen Horowitz, 500 Startups, Kapor Capital, Bansea, Linden Mobile Ventures, Three Bridges Venture Partners, Milliways Ventures, BoxGroup

Microbiomics $4.97M

GoodGut(2014, Girona)

Diagnosis and treatment of digestive diseases based on intestinal microbiota analysisCaixa Capital Risc, BAGi

Microbiomics $852.5k

IS-Diagnostics(2011, Amsterdam)

Provider of technology that enables the diagnosis, ongoing tracking and management of bacterial populations in various habitats. Microbiomics

OmniBiome(2012, San Diego)

Diagnostics, therapeutics for pregnancy-associated conditions where there is a substantive link with microbiome / microbiota dysbiosis. Microbiomics

Quantibio(2014, Beijing)

Focuses on the gene mapping of human gut microbiomeGlobals Tech. Microbiomics



Clinical Genomics (4/26)



Bioinformatics (1/25)

Clinical

Genomics << Go to BM List >>

Sequencing

Technology



Clinical


Sequencing

Technology


Sequencing Technology (1/5)

Bioinformatics << Go to BM List >> Genetic Testing


Genetic Testing (1/11)

Sequencing

Technology<< Go to BM List >> Liquid Biopsy



Sequencing



Liquid Biopsy (1/7)

Genetic Testing << Go to BM List >>Research

Genomics


Liquid Biopsy (2/7)


Genomics


Liquid Biopsy (3/7)


Genomics


Liquid Biopsy (4/7)


Genomics


Liquid Biopsy (5/7)


Genomics


Liquid Biopsy (6/7)


Genomics


Liquid Biopsy (7/7)


Genomics


Research Genomics (1/12)

Liquid Biopsy << Go to BM List


Scope of Report


Investment Trend

Who is Investing


Sub Sector Analysis


Company List

Team

142


Team

143

Shubham Garg

Senior Analyst, Life Sciences

Subhabrata Pal

Lead Analyst, Life Sciences

Vikash Peesapati

Lead Analyst, Life Sciences

https://www.linkedin.com/in/shubhamgarg642

http://www.twitter.com/tracxnhealth

https://in.linkedin.com/in/subhabratap

https://twitter.com/shubho_p

https://www.linkedin.com/in/vikashpeesapati

http://www.twitter.com/tracxnhealth

tracxn research — genomics landscape, november 2016

Data & Analytics